Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-48919

ABSTRACT: Gene expression analysis of OVCAR-3 and CDK2 resistant sublines

OTHER RELATED OMICS DATASETS IN: PRJNA212315PRJNA212314PRJNA212313

PROVIDER: E-GEOD-48919 | ExpressionAtlas | 2015-07-21

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-48919-analysis-methods.tsv	Tabular
	E-GEOD-48919-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-48919-configuration.xml	Xml
	E-GEOD-48919-percentile-ranks.tsv	Tabular
	E-GEOD-48919.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 69

Similar Datasets

TR study of ‘A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (BIGBANG study)&quot

Project description:Primary outcome(s): Cancer related genome analysis, gene expression and molecular characterization analysis

| 2647002 | ecrin-mdr-crc

Differential Protein and Gene Expression in Endocrine and Neuroendocrine Tumors (NET)

Project description:Interventions: Group 1: Quantitative Expression Analysis of the proteom and gene Expression of Primary Tumor, normal tissue, and metastases Primary outcome(s): Disease associated Proteins and Genes Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science

| 2431957 | ecrin-mdr-crc

TR accompanied with the study titled A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H).

Project description:Primary outcome(s): 1. Evaluation of genome abnormality and gene expression by omics analysis of tumor etc. 2. TCR repertoire analysis and RNA expression analysis etc. of T cells in tumor tissue and peripheral blood. 3. Prediction and identification of tumor neo-antigen and evaluation of immunogenicity etc. 4. Analyze ctDNA(16S rRNA PCR) and feces of patients with advanced solid malignancies over time to profile and monitor cancer-related genomic alterations 5. Assessment of the relationship between the analysis above and clinical pathological features or therapeutic efficacy etc.

| 2648665 | ecrin-mdr-crc

Biomarks of Resistance to Cetuximab in Colorectal Cancer

Project description:Interventions: A group:Before using cetuximab;B group:After progression of disease:no Primary outcome(s): KRAS gene sequence;NRAS gene sequence;BRAF gene sequence;PIK3CA gene sequence;EGFR gene sequence;EGFR gene copy numbers;EGFR expression;Her2 expression;c-Met expression;PTEN expression Study Design: historical control

| 2671639 | ecrin-mdr-crc

Homo sapiens

Project description:Gene expression analysis of imatinib-resistant GIST

| PRJNA285670 | ENA

Identification of the molecular basis of anti-cancer effect of Huaier.

Project description:Intervention type:DRUG. Intervention1:Huaier, Dose form:GRANULES, Route of administration:ORAL, intended dose regimen:20 to 60/day by either bulk or split for 3 months to extended term if necessary. Control intervention1:None. Primary outcome(s): For mRNA libraries, focus on mRNA studies. Data analysis includes sequencing data processing and basic sequencing data quality control, prediction of new transcripts, differential expression analysis of genes. Gene Ontology (GO) and the KEGG pathway database are used for annotation and enrichment analysis of up-regulated genes and down-regulated genes. For small RNA libraries, data analysis includes sequencing data process and sequencing data process QC, small RNA distribution across the genome, rRNA, tRNA, alignment with snRNA and snoRNA, construction of known miRNA expression pattern, prediction New miRNA and Study of their secondary structure Based on the expression pattern of miRNA, we perform not only GO / KEGG annotation and enrichment, but also different expression analysis.. Timepoint:RNA sequencing of 240 blood samples of 80 cases and its analysis, scheduled from June 30, 2022..

| 2612481 | ecrin-mdr-crc

Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells

Project description:Multiple myeloma RPMI8226 cells adapted to growth in melphalan display a shift towards Warburg metabolism and modulated oxidative stress signaling. Inhibitors targeting specific enzymes in these pathways are selectively toxic to the melphalan-resistant cells. To investigate large scale alterations in gene expression accompanying melphalan resistance, we used the multiple myeloma cell line RPMI8226 and its melphalan-resistant derivative LR5. The stable isotope labeling by amino acids in cell culture (SILAC) approach.

2015-05-26 | PXD001276 | Pride

TR study of ‘multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer&quot

Project description:Primary outcome(s): Cancer-related gene alteration, expression of protein, and expression of RNA

| 2645675 | ecrin-mdr-crc

Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1.

Project description:Primary objectives: Evaluate the effect of the imipramine treatment on the development of histological manifestations associated with the mesenchymal epithelial transition during the period of time from the analysis of the diagnostic biopsy to the surgical resection intervention. Primary endpoints: Comparison of the histological traits of invasive tumour front of the surgical tumour resection specimen between the intervention group and the placebo group:1. Fascin1 expression in tumour tissue: It will be analysed by immunohistochemistry and the application of Immunoscore.2. Histological manifestations of the epithelial-mesenchymal transition (EMT): Tumour budding, cytoplasmic pseudo-fragments, infiltrating growth pattern and poorly differentiated nests. It will be evaluated by histological analysis.3. Invasive histological manifestations: discontinuous extramural extension, lymphatic, venous and perineural infiltration. It will be evaluated by histological analysis.4. Histological manifestation of the immune response: Peritumoral and intratumour lymphocyte infiltration. It will be evaluated by histological analysis.5. EMT molecular manifestations: FSCN1, SNAIL and SLUG gene expression. It will be evaluated by NGS analysis of the primary tumour.

| 2541275 | ecrin-mdr-crc

TR study of ‘A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)&quot

Project description:Primary outcome(s): cancer-related gene alteration, gene expression, microsatellite instability, BRAF mutant allele frequency

| 2646701 | ecrin-mdr-crc